Swiss pharmaceutical leader Roche has announced a significant investment of $50 billion in the United States over the next five years. This initiative is expected to generate over 12,000 new jobs, including 6,500 construction roles and 1,000 positions at new and expanded facilities.
The investment will bolster Roche’s U.S. operations, which currently employ 25,000 people across 24 sites. Key projects include the expansion of manufacturing and distribution centers in Kentucky, Indiana, New Jersey, and California, as well as the construction of a gene therapy factory in Pennsylvania and a continuous glucose monitoring plant in Indiana. Additionally, a new research center in Massachusetts will focus on cardiovascular, renal, and metabolism studies, while a facility for weight loss medicines is planned, with the location yet to be announced.
Roche’s Chief Executive, Thomas Schinecker, emphasized the company’s commitment to innovation and growth, stating that the investment would benefit patients in the U.S. and globally. The move also aligns with Roche’s goal to export more medicines from the U.S. than it imports, further strengthening its position as a global pharmaceutical leader.